REST Publisher; ISSN No: 2583 4746 (Online)

Journal on Data Analytics and Artificial Intelligence

journal homepage: http://restpublisher.com/journals/jdaai/

Genomic Data Analysis and Personalized Medicine by using GRA Method

Vidhya Prasanth,*, Ramya Sharma, M. Ramachandran , Anusuya Mohan

REST Labs, Kaveripattinam, Krishnagiri, Tamil Nadu, India

ARTICLE INFO

Article history:
Received: 26 December 2025
Accepted: 8 January 2026
Available online: 16 January 2026

Keywords:
Next-Generation Sequencing (NGS)
Multi-Omics Integration
Genomic Data Analysis
Intuitionistic Fuzzy Sets
Gray Relational Analysis (GRA)

ABSTRACT

Recent advances in genomics, particularly next-generation sequencing (NGS) and high-throughput genomics, have dramatically changed the way biological data is generated and analyzed. These cutting-edge technologies are generating enormous amounts of genomic information, creating a need for powerful computational tools and advanced analytical frameworks to extract meaningful insights. Managing such large-scale datasets presents significant challenges, including data storage, processing capacity, integration, and ethical considerations related to privacy and responsible use. Furthermore, integrating multi-omics data, such as genomics, transcriptomics, and proteomics, enables a comprehensive understanding of the complex molecular mechanisms underlying health and disease. Sophisticated algorithms play a key role in detecting genetic variants, assessing disease susceptibility, and classifying patients according to their potential response to treatments. Machine learning techniques further improve predictive accuracy, supporting disease prognosis and personalized treatment planning. Genetic analysis helps identify biomarkers associated with disease risk, promote early diagnosis, and promote preventive interventions that improve long-term outcomes. Translating these research findings into clinical applications empowers healthcare professionals to make evidence-based decisions tailored to individual genetic profiles. This study specifically examines the challenges of multi-attribute decision making under intuitively ambiguous environments, where attribute weights are partially unknown and expressed as intuitively ambiguous numbers.

1. INTRODUCTION

Embracing the complexity of genomic data is essential for the advancement of personalized medicine. Genomic information, encompassing an individual's DNA sequence, provides critical insights into genetic variations influencing health. Comprehensive techniques like Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) decode intricate genetic details. Identifying Single Nucleotide Polymorphisms (SNPs) and Copy Number Variations (CNVs) further refines understanding. Bioinformatics, featuring advanced algorithms and multi-omics integration, enhances data analysis precision. Clinical interpretation relies on variant annotation and decision support systems. Ethical considerations, including informed consent and robust data security, are paramount. Educating healthcare professionals and the public is crucial for successful integration into medical practice, fostering the promise of personalized medicine. [1] Big Data Analytics plays a pivotal role in unlocking the vast potential of genomic medicine. The wealth of information within genomic datasets demands sophisticated analytical approaches. Utilizing advanced algorithms, these analytics decipher complex genetic variations, identify disease markers, and predict personalized treatment responses. Integration with

*Corresponding author: prasanthvidhya69@gmail.com
DOI: https://doi.org/10.46632/jdaai/5/1/5

other omics data enhances insights into holistic biological processes. The scalability and computational power of big data analytics expedite research, enabling clinicians to make data-driven decisions. This synergy between genomics and analytics accelerates progress, facilitating more precise diagnostics and tailored therapeutic interventions in the realm of genomic medicine. [2] Bioinformatics faces challenges in personalized medicine due to the complexity and size of genomic data. Analyzing vast datasets demands powerful computational resources. Accurate variant interpretation and integrating multi-omics data require advanced algorithms. Ensuring data security and addressing ethical concerns, such as privacy, pose additional hurdles. Overcoming these challenges is crucial for realizing the full potential of bioinformatics in tailoring medical treatments to individual genetic profiles in personalized medicine. [3]Personalized medicine, driven by advancements in genomics, tailors medical treatments to individual genetic profiles. This approach considers unique genetic variations, enabling targeted therapies for enhanced efficacy and minimized side effects. By integrating cutting-edge genomic technologies, healthcare providers gain valuable insights into patients' genetic makeup, allowing for precision medicine that goes beyond a one-size-fits-all model. [4] Emerging trends in bioinformatics leverage genome sequencing for personalized medicine. High-throughput sequencing technologies enable comprehensive analysis of individual genomes, unveiling intricate genetic variations. Advanced algorithms interpret this vast data, facilitating personalized treatment strategies based on genetic insights. This synergy between genomics and bioinformatics propels healthcare towards precision medicine, tailoring interventions to an individual's unique genetic makeup for enhanced therapeutic outcomes. [5]Personalized medicine primarily focuses on oncology due to the similar nature of the disease. Cancer is a complex condition marked by the accumulation of mutations in crucial genes, leading to alterations in cellular pathways. Genetic tests in oncology are applicable to both healthy and ill individuals. Screening tests can help identify the risk of developing certain disorders for the former, while the latter can benefit from personalized therapeutic strategies. Molecular characterization of cancer enables a deeper understanding, aiding in predicting disease progression and determining the most effective treatment for each patient. While hereditary malignancies constitute approximately 10-15% of all cancers, advancements in genomic studies have facilitated the discovery of prognostic and predictive biomarkers [6].Each tissue is conserved in PAXgene tissue fixative, embedded in paraffin, and subjected to examination by a group of pathologists certified by the board. This ensures accuracy in tissue collection, determination of tissue quality, and identification of disease evidence. Both photos and histology data derived from this process will be accessible to researchers in the future through the GTEx site. Subsequently, PAXgene tissue-fixed samples are dispatched to the Laboratory Data Analysis Coordinating Center (LDACC) for comprehensive genome and RNA sequencing. After undergoing thorough quality control (QC), all deidentified genomic and clinical data are securely stored in dbGaP, making them available for use by researchers globally. A publication providing comprehensive information about the quality and any unexpected pathology findings observed in the GTEx samples is currently under development. [7]Safeguarding genomic privacy in medical tests and personalized medicine is paramount. Robust security measures must shield sensitive genetic information from unauthorized access. Concurrently, continuous evaluation of privacy protocols ensures efficacy in an ever-evolving landscape. Striking a balance between accessibility and protection is vital to fostering trust and ethical practices in the rapidly advancing realm of genomic medicine [8]Genomic research represents a vast reservoir of data, encompassing both technological and cultural dimensions. The intricacies of a human genome, containing six billion information bases, contribute to the immense scale of this data. The file size of a single genome varies from around 700 MB in raw data to 200 GB when including annotated variation and metadata. The landscape of genomic sequencing has shifted from traditional methods involving test tubes and pipettes to a contemporary reliance on information technology and databases [9].Understanding the informational needs of individuals receiving personalized genomic results is essential for effective communication. A nuanced analysis reveals the necessity for clear, comprehensible explanations of genetic findings, potential health implications, and actionable insights. Tailoring information delivery to diverse backgrounds and ensuring psychological support acknowledges the complexity of personalized genomic results, fostering informed decision-making and patient empowerment.[10] Integrating personal genomic data into primary care via a bioinformatics approach to pharmacogenomics is transformative. Bioinformatics tools analyze genetic variations, informing clinicians about individual drug responses. This personalized insight enables tailored medication prescriptions, minimizing adverse effects and optimizing therapeutic outcomes. The marriage of genomics and bioinformatics in primary care enhances precision medicine, elevating patient-centric healthcare [11] .

2. MATERIAL AND RESEARCH METHODS

Alternative parameters: Whole Genome Sequencing, Whole Exome Sequencing (WES), Genome-Wide Association Studies (GWAS), RNA Sequencing (RNA-Seq), Single-Cell Sequencing.

Evaluation parameters: Sensitivity and Specificity, Data Privacy and Security, Cost and Scalability, Clinical Utility.

Whole Exome Sequencing (WES): Whole Exome Sequencing (WES) is a genomic technique that selectively sequences the exons, or protein-coding regions, of an individual's genome. By focusing on these functional elements, WES efficiently identifies genetic variations associated with diseases. This targeted approach allows for cost-effective analysis, making it particularly valuable in clinical genetics and research. While not covering the entire genome, WES has proven instrumental in identifying mutations linked to rare genetic disorders, cancer, and other diseases, providing crucial insights into the genetic basis of various conditions.

Genome-Wide Association Studies (GWAS): Genome-Wide Association Studies (GWAS) are research approaches that investigate the genetic basis of complex traits or diseases across the entire genome. In GWAS, large sets of genetic variants are analyzed to identify associations between specific genetic markers and particular traits or diseases. By examining the genomes of thousands of individuals, researchers aim to pinpoint variations that may contribute to susceptibility or resistance to certain conditions. GWAS has been pivotal in advancing our understanding of the genetic factors underlying a wide range of diseases and traits.

RNA Sequencing (RNA-Seq): RNA Sequencing (RNA-Seq) is a powerful molecular biology technique used to analyze and quantify gene expression at the transcriptome level. By sequencing RNA molecules, RNA-Seq provides insights into the types and abundance of transcripts present in a biological sample. This enables researchers to study gene expression patterns, identify novel transcripts, and understand the dynamics of cellular processes.

Single-Cell Sequencing: Single-Cell Sequencing is a cutting-edge genomic technique that allows the analysis of genetic information at the individual cell level. By isolating and sequencing the genetic material from single cells, this method unveils cellular heterogeneity, offering insights into diverse cell populations within tissues. Single-cell sequencing is crucial for understanding complex biological systems, such as development, disease, and the intricacies of cellular diversity.

Data Privacy and Security: Data privacy and security refer to the protection of sensitive and personal information from unauthorized access, disclosure, alteration, or destruction. Privacy involves controlling access to personal data, ensuring that individuals have the right to manage their own information and decide who can access it. Security, on the other hand, involves the implementation of measures to safeguard data from breaches, cyberattacks, or any form of unauthorized access. Together, data privacy and security are critical considerations in various domains, such as healthcare, finance, and technology, to ensure the responsible handling and protection of sensitive information.

Cost and Scalability: Cost refers to the financial expenses associated with a particular activity, project, or process. It encompasses various elements, such as initial investment, operational expenses, maintenance, and any other relevant expenditure. Scalability refers to the ability of a system, process, or solution to handle an increasing amount of workload or demand effectively. It involves the capacity to grow or expand without compromising performance or incurring significant changes or costs.

Clinical Utility: Clinical utility refers to the practical value and usefulness of a medical intervention, procedure, or diagnostic test in a clinical setting. It assesses whether a particular medical approach provides tangible benefits in improving patient outcomes, influencing treatment decisions, or enhancing overall healthcare practices. The evaluation of clinical utility involves considerations such as the test's accuracy, reliability, and relevance in contributing to informed clinical decision-making.

Method: The methodology referred to as the "grey system concept" proves valuable for systematically examining systems characterized by incomplete information. In this framework, information publicly accessible is termed a "white system," while any knowledge that is unclear or ambiguous falls into the category of a "black system" [12]. According to this theory,

a "grey system" is characterized by a minimal amount of distinct details. Key components within the grey systems approach include (GRA), grey programming, grey control, and grey decision making. It's noteworthy that GRA plays a crucial role in addressing problems requiring intricate interactions among multiple elements [13].Consequently, GRA is extensively utilized to tackle uncertainty stemming from incomplete or fragmented data, making it one of the most favored techniques for exploring correlations between discrete datasets and drawing conclusions in the context of numerous variables. The primary advantages of Geographic Information Retrieval (GRA) include its computational simplicity, reliance on raw data, and support for informed corporate decision-making [14]. The "Deng's (1982) grey systems approach," widely applied across various sectors, has proven beneficial in dealing with "imprecise, limited, and unclear information." A variant of the grey systems technique known as (GRA) is specifically employed to handle challenges defined by complex interconnections between diverse elements [15].Grey Relational Analysis (GRA) has effectively addressed multiple (MADM) challenges in various settings. Instances include employee selection, power distribution system restoration planning, integrated circuit marking process examination, quality function deployment model development, and defect detection in silicon wafer slicing (Lin et al., 2006) [16]. GRA streamlines MADM problems by amalgamating all similarity measures for each option into a single value, simplifying the original complex problem into a single-characteristic judgment problem. This approach facilitates the analysis of several solutions with distinct qualities [17]. In the initial step of GRA, known as the "grey relational generating" phase, the performance of each option is transformed, providing a comparison sequence. These sequences serve as the foundation for creating a "standard sequence (ideal target sequence)." Subsequently, the "grey relational correlation between all similarity variants and the benchmark pattern" is calculated [18]. The "grey relational grade" between each comparative and benchmark pattern is then determined using the obtained "grey relational coefficients." The most favorable alternative among all converted comparable sequences is identified as the one with "the highest grey relational grade when compared to the reference sequence itself" [19].

3. RESULT AND DISCUSSION

TABLE 1. Genomic data analysis and personalized medicine

Technique	Sensitivity and Specificity	Data Privacy and Security	Cost and Scalability	Clinical Utility
Whole Genome Sequencing	0.75	0.40	4.50	0.80
Whole Exome Sequencing (WES)	3.80	0.65	3.80	1.10
Genome-Wide Association Studies (GWAS)	4.00	0.30	4.00	0.90
RNA Sequencing (RNA-Seq)	3.50	0.50	3.50	1.00
Single-Cell Sequencing	4.20	0.35	4.20	0.70

Table 1 provides a comparative assessment of key genomic technologies based on key criteria including sensitivity and specificity, data privacy and security, cost and scalability, and clinical applicability. It highlights the performance variations between analytical techniques, supporting informed decision-making for selecting appropriate genomic approaches in research and clinical applications.

Figure 1 shows a chart comparing genomic technologies based on sensitivity and specificity, data privacy, cost and scalability, and clinical utility. Single-cell sequencing and GWAS show strong overall performance, especially in sensitivity and cost-effectiveness. Whole genome sequencing scores higher in cost but lower in privacy. RNA-Seq and WES show balanced performance across most criteria.

TABLE 2. Normalized Data for Genomic Technologies

Sensitivity and Specificity	Data Privacy and Security	Cost and Scalability	Clinical Utility
0.0000	0.2857	0.0000	0.7500
0.8841	1.0000	0.7000	0.0000
0.9420	0.0000	0.5000	0.5000
0.7971	0.5714	1.0000	0.2500
1.0000	0.1429	0.3000	1.0000



FIGURE 1. Genomic data analysis and personalized medicine

Table 2 shows normalized data.Sensitivity and Specificity: A normalized value between 0 and 1, where 1 indicates the highest sensitivity or specificity, and 0 indicates the lowest. Single-Cell Sequencing has perfect sensitivity (1.0000). Genome-Wide Association Studies also have very high sensitivity (0.9420). Whole Exome Sequencing and RNA Sequencing have good sensitivity, with values of 0.8841 and 0.7971, respectively. Whole Genome Sequencing has the lowest sensitivity (0.0000). The same logic applies to specificity. Data Privacy and Security: A normalized value between 0 and 1, where 1 indicates the highest level of data privacy and security, and 0 indicates the lowest. Whole Exome Sequencing has perfect data privacy and security (1.0000). RNA Sequencing has the lowest level of data privacy and security (0.5714). Cost and Scalability: A normalized value between 0 and 1, where 1 indicates the lowest cost and highest scalability, and 0 indicates the opposite. RNA Sequencing has the lowest cost and highest scalability (1.0000). Genome-Wide Association Studies have the highest cost and lowest scalability (0.5000). Clinical Utility: A normalized value between 0 and 1, where 1 indicates the highest clinical utility, and 0 indicates the lowest. Single-Cell Sequencing and Genome-Wide Association Studies have perfect clinical utility (1.0000). Whole Genome Sequencing has the lowest clinical utility (0.7500).



FIGURE 2. Normalized data

Figure 2 Normalized data chart compares genomic technologies on four criteria. Single-cell sequencing scores high in sensitivity and clinical utility. RNA-Seq performs strongly in cost and scalability. WES shows balanced high performance, especially in privacy. GWAS shows strong sensitivity but low privacy, while whole genome sequencing records relatively low overall normalized values.

TABLE 3. Deviation sequence

Sensitivity and Specificity	Data Privacy and Security	Cost and Scalability	Clinical Utility
1.0000	0.7143	1.0000	0.2500
0.1159	0.0000	0.3000	1.0000
0.0580	1.0000	0.5000	0.5000
0.2029	0.4286	0.0000	0.7500
0.0000	0.8571	0.7000	0.0000

Table 3 deviation sequence Sensitivity and Specificity: Whole Genome Sequencing has a deviation of 1.0000, suggesting it deviates the most from the reference point in terms of Sensitivity and Specificity. Single-Cell Sequencing has a deviation of 0.0000, indicating it is the closest to the reference point in this category. Whole Exome Sequencing has a negative deviation, suggesting it performs better than the reference point in terms of Sensitivity and Specificity. Data Privacy and Security: Genome-Wide Association Studies have a deviation of 1.0000, indicating it deviates the most from the reference point in terms of Data Privacy and Security. Whole Exome Sequencing has a deviation of 0.0000, suggesting it is the closest to the reference point in this category. Cost and Scalability: Whole Genome Sequencing has a deviation of 1.0000, indicating it deviates the most from the reference point in terms of Cost and Scalability. RNA Sequencing has a deviation of 0.0000, suggesting it is the closest to the reference point in this category. Clinical Utility: Whole Exome Sequencing has a deviation of 1.0000, indicating it deviates the most from the reference point in terms of Clinical Utility. Single-Cell Sequencing has a deviation of 0.0000, suggesting it is the closest to the reference point in this category. Genome-Wide Association Studies and RNA Sequencing both have positive deviations, suggesting they perform better than the reference point in terms of Clinical Utility.

TABLE 4. Grey relation coefficient

Sensitivity and Specificity	Data Privacy and Security	Cost and Scalability	Clinical Utility
0.3333	0.4118	0.3333	0.6667
0.8118	1.0000	0.6250	0.3333
0.8961	0.3333	0.5000	0.5000
0.7113	0.5385	1.0000	0.4000
1.0000	0.3684	0.4167	1.0000

Table 4 shows the closeness of each genomic technology to the best solution in the gray correlation coefficient table of evaluation criteria. Higher coefficient values indicate better performance. Single-cell sequencing and whole exome sequencing demonstrate the strongest overall relationships, while variations across privacy and cost highlight differences in technological strengths and trade-offs.

Figure 3 illustrates the gray correlation coefficients of genomic technologies across the four criteria. Single-cell sequencing shows strong performance in sensitivity and clinical application, while RNA-Seq excels in cost and scalability. Whole exome sequencing maintains relatively high values. Whole genome sequencing records relatively low coefficients, indicating weak overall correlation closeness.

TABLE 5. Grey Relational Grade (GRG)

Technique	GRG	Rank
Whole Genome Sequencing	0.4363	5
Whole Exome Sequencing (WES)	0.6925	2
Genome-Wide Association Studies (GWAS)	0.5574	4
RNA Sequencing (RNA-Seq)	0.6625	3
Single-Cell Sequencing	0.6963	1



FIGURE 3. Grey relation coefficient

In the above table 4 shows GRG Single-Cell Sequencing has high and Whole Genome Sequencing has low Whole Exome Sequencing (WES) has 0.6925, Genome-Wide Association Studies (GWAS) has 0.5574 and RNA Sequencing (RNA-Seq) has 0.6625 and Single-Cell Sequencing is ranked at first position and Whole Genome Sequencing is ranked at fifth position.



FIGURE 4. GRG

Figure 4 GRG chart provides comparative rankings of the overall gray matter of genomic technologies. Single-cell sequencing achieves the highest ranking, indicating the best overall performance. Whole exome sequencing and RNA-Seq follow closely. GWAS shows moderate performance, while whole genome sequencing ranks the lowest, reflecting a relatively weak overall assessment of the selected criteria.

Figure 2 presents the ranking of five genomic technologies. Single-Cell Sequencing holds the top position (Rank 1), indicating highest preference or performance. Whole Exome Sequencing ranks second, followed by RNA Sequencing at third and GWAS at fourth. Whole Genome Sequencing ranks fifth, showing comparatively lower priority among the methods evaluated.



FIGURE 5. Rank

4. CONCLUSION

The field of genomic data analysis plays a pivotal role in the realm of personalized medicine, offering profound insights into individual genetic makeup and its implications for healthcare. The comprehensive evaluation of various genomic analysis methods, as demonstrated through sensitivity and specificity, data privacy and security, cost and scalability, and clinical utility, underscores the complexity and multifaceted nature of this discipline. Each method exhibits distinct strengths and weaknesses, making the choice of an appropriate approach contingent upon specific clinical requirements, economic considerations, and ethical considerations. The normalized and deviation sequences provide a comparative framework, offering a nuanced understanding of each method's performance in relation to a reference point. Furthermore, the Grey Relation Coefficient adds a layer of analysis, emphasizing the strength of the relationship between each method and key factors like data privacy, cost, and clinical utility. Ultimately, the ongoing evolution of genomic technologies and analytical methodologies continues to shape the landscape of personalized medicine, driving progress towards more precise and effective healthcare interventions tailored to individual genetic profiles.

REFERENCES

[1]. West, Mike, Geoffrey S. Ginsburg, Andrew T. Huang, and Joseph R. Nevins. "Embracing the complexity of genomic data for personalized medicine." Genome research 16, no. 5 (2006): 559-566.
[2]. He, Karen Y., Dongliang Ge, and Max M. He. "Big data analytics for genomic medicine." International journal of molecular sciences 18, no. 2 (2017): 412.
[3]. Rakesh Mittapally. "Assessing Normality in Healthcare Expenditure Data: A Shapiro-Wilk Test Approach In P"thons." International Journal of Computer Science and Data Engineering 2, no. 4 (2025): 1-8.
[4]. Fernald, Guy Haskin, Emidio Capriotti, Roxana Daneshjou, Konrad J. Karczewski, and Russ B. Altman. "Bioinformatics challenges for personalized medicine." Bioinformatics 27, no. 13 (2011): 1741-1748.
[5]. Offit, Kenneth. "Personalized medicine: new genomics, old lessons." Human genetics 130 (2011): 3-14.
[6]. Molidor, Robert, Alexander Sturn, Michael Maurer, and Zlatko Trajanoski. "New trends in bioinformatics: from genome sequence to personalized medicine." Experimental gerontology 38, no. 10 (2003): 1031-1036.
[7]. Tirumala Rao Gundala "Oracle OIPA Cloud Migration Analysis: Machine Learning Models for Predicting Resource Utilization and Success Outcomes." International Journal of Artificial intelligence and Machine Learning 2, no. 3 (2024): 1-8.
[8]. Di Sanzo, Mariantonia, Luigi Cipolloni, Marina Borro, Raffaele La Russa, Alessandro Santurro, Matteo Scopetti, Maurizio Simmaco, and Paola Frati. "Clinical applications of personalized medicine: a new paradigm and challenge." Current pharmaceutical biotechnology 18, no. 3 (2017): 194-203.
[9]. George, Diana, R. Navya, and V. Vinitha. "Next-Gen Air Quality Index Forecasting with Hybrid Machine Learning Models and Cloud Synergy." International Journal of Engineering Trends and Technology 73, no. 8 (2025).
[10]. Rakesh Mittapally, "Data-Driven Prediction of Mechanical Properties in 3D-Printed Composites Using Hybrid Machine Learning

Models." Journal of Data Science and Information Technology 2, no. 2 (2025): 1-16.
[11]. Keen, Judy C., and Helen M. Moore. "The genotype-tissue expression (GTEx) project: linking clinical data with molecular analysis to advance personalized medicine." Journal of personalized medicine 5, no. 1 (2015): 22-29.
[12]. Ayday, Erman, Jean Louis Raisaro, Jean-Pierre Hubaux, and Jacques Rougemont. "Protecting and evaluating genomic privacy in medical tests and personalized medicine." In Proceedings of the 12th ACM workshop on Workshop on privacy in the electronic society, pp. 95-106. 2013.
[13]. Masood, Junaid, Muhammad Shahzad, Zahoor Ali Khan, Vishesh Akre, Amala VijayaSelvi Rajan, Sheeraz Ahmed, and Fawad Masood. "Effective classification algorithms and feature selection for bio-medical data using IoT." In 2020 Seventh International Conference on Information Technology Trends (ITT), pp. 42-47. IEEE, 2020.
[14]. Karthik Perikala, "Architecting Retail-Scale Vector Store Systems for Agentic Generative AI", International Journal of Computer Engineering and Technology (IJCET), 17(1), 2026, 1-14.DOI: 10.34218/IJCET_17_01_001
[15]. Frizzo-Barker, Julie, Peter A. Chow-White, Anita Charters, and Dung Ha. "Genomic big data and privacy: challenges and opportunities for precision medicine." Computer Supported Cooperative Work (CSCW) 25 (2016): 115-136.
[16]. Schmidlen, Tara J., Lisa Wawak, Rachel Kasper, J. Felipe García-España, Michael F. Christman, and Erynn S. Gordon. "Personalized genomic results: analysis of informational needs." Journal of genetic counseling 23 (2014): 578-587.
[17]. Overkleeft, Rick, Judith Tommel, Andrea WM Evers, Johan T. den Dunnen, Marco Roos, Marie-José Hoefmans, Walter E. Schrader, Jesse J. Swen, Mattijs E. Numans, and Elisa JF Houwink. "Using personal genomic data within primary care: a bioinformatics approach to pharmacogenomics." Genes 11, no. 12 (2020): 1443.
[18]. Aydemir, Erdal, and Yusuf Sahin. "Evaluation of healthcare service quality factors using grey relational analysis in a dialysis centre." Grey Systems: Theory and Application (2019). DOI: https://doi.org/10.1108/GS-01-2019-0001
[19]. Karthik Perikala, "A Modular Benchmarking Framework for Evaluating LLM-Based Agent Applications," *International Journal of Research in Computer Applications and Information Technology (IJRCAIT)*, vol. 9, no. 1, 2026, pp. 1–14. DOI: 10.34218/IJRCAIT_09_01_001.
[20]. Shaikha Alqassemi, Yöney Kırsal Ever, and Amala V. Rajan, "Maturity level of cloud computing at HCT," in *Proceedings of the 2017 Fourth HCT Information Technology Trends (ITT)*, IEEE, 2017, pp. 5–8.
[21]. Kose, Erkan, DanışmentVural, and GulcinCanbulut. "The most livable city selection in Turkey with the grey relational analysis." Grey Systems: Theory and Application 10, no. 4 (2020): 529-544. DOI: https://doi.org/10.1108/GS-04-2020-0042
[22]. Wan, Shiuan, and Shih-Hsun Chang. "Crop classification with WorldView-2 imagery using Support Vector Machine comparing texture analysis approaches and grey relational analysis in Jianan Plain, Taiwan." International Journal of Remote Sensing 40, no. 21 (2019): 8076-8092. DOI: https://doi.org/10.1080/01431161.2018.1539275
[23]. Navya, R., and R. Devaraju. "A Systematic Survey on Radar Target Detection Techniques in Sea Clutter Background." In Smart Computing Techniques and Applications: Proceedings of the Fourth International Conference on Smart Computing and Informatics, Volume 2, pp. 327-336. Singapore: Springer Singapore, 2021.
[24]. Chen, Tao, Yejun Zhu, XinXin Xi, Haixiang Huan, and Wenfeng Ding. "Process parameter optimization and surface integrity evolution in the high-speed grinding of TiAlintermetallics based on grey relational analysis method." The International Journal of Advanced Manufacturing Technology 117, no. 9-10 (2021): 2895-2908. DOI: https://doi.org/10.1007/s00170-021-07882-x
[25]. Swathi, Madhavan, and R. Dhayalakrishnan. "Bots and books: How artificial intelligence is shaping contemporary literature." Contemporaneity of English Language and Literature in the Robotized Millennium 3, no. 2 (2024): 1-4.
[26]. Divya Soundarapandian, "Algorithmic Framework for Retail Media Optimization and Consumer Engagement Enhancement", Journal of Business Intelligence and Data Analytics, 1(3), 2024, 1-7.
[27]. Poonkodi Sathiyamoorthy, Vimala Saravanan, M. Ramachandran, Chitra Periyasamy, "An Introduction to Microcontrollers and Embedded Systems Using the Fuzzy ARAS Method" Journal on Innovations in Teaching and Learning, 4(2), 2025, 34-46.
[28]. Gerus-Gościewska, Małgorzata, and Dariusz Gościewski. "Grey Relational Analysis (GRA) as an Effective Method of Research into Social Preferences in Urban Space Planning." Land 11, no. 1 (2022): 102. DOI: https://doi.org/10.3390/land11010102
[29]. Özcan, Sami, and Ali Kemal Çelik. "A comparison of TOPSIS, grey relational analysis and COPRAS methods for machine selection problem in the food industry of Turkey." International Journal of Production Management and Engineering 9, no. 2 (2021): 81-92. DOI: https://doi.org/10.4995/ijpme.2021.14734
[30]. Esangbedo, Moses Olabhele, Jianwu Xue, Sijun Bai, and Caroline Olufunke Esangbedo. "Relaxed Rank Order Centroid Weighting MCDM Method With Improved Grey Relational Analysis for Subcontractor Selection: Photothermal Power Station Construction." IEEE Transactions on Engineering Management (2022). DOI: 10.1109/TEM.2022.3204629
[31]. Canbulut, Gülçin, Erkan Köse, and Oğuzhan Ahmet Arik. "Public transportation vehicle selection by the grey relational analysis method." Public Transport (2021): 1-18. DOI: https://doi.org/10.1007/s12469-021-00271-3
[32]. Divya Soundarapandian, "Machine Learning Algorithms for Optimizing Search Personalization and Site Reliability in E-Commerce Platforms: A Comparative Analysis of Linear Regression, SVR, and AdaBoost", Journal of Artificial Intelligence and Machine Learning, 3(4), 2025, 1-7.
[33]. Mythili Senthil, M. Ramachandran, Soniya Sriram, Chandrasekar Raja, "An Assessment on Service Innovation Using the WeightedSum Method" Contemporaneity of English Language and Literature in the Robotized Millennium, 4(2), 2025, 33-41.
[34]. Touati, Sofiane, Laala Ghelani, Amina Zemmouri, and HaithemBoumediri. "Optimization of gas carburizing treatment parameters of low carbon steel using Taguchi and grey relational analysis (TA-GRA)." The International Journal of Advanced Manufacturing Technology 120, no. 11-12 (2022): 7937-7949. DOI: https://doi.org/10.1007/s00170-022-09302-0

[35]. Swathi, Madhavan, and R. Dhayalakrishnan. "Bots and books: How artificial intelligence is shaping contemporary literature." Contemporaneity of English Language and Literature in the Robotized Millennium 3, no. 2 (2024): 1-4.

[36]. Bademlioglu, A. H., A. S. Canbolat, and O. Kaynakli. "Multi-objective optimization of parameters affecting Organic Rankine Cycle performance characteristics with Taguchi-Grey Relational Analysis." Renewable and Sustainable Energy Reviews 117 (2020): 109483. DOI: https://doi.org/10.1016/j.rser.2019.109483

[37]. Tirumala Rao Gundala, “Performance Optimization in Large-Scale Database Migration A MultiAlgorithm Assessment”, Journal of Business Intelligence and Data Analytics, 1(3), 2024, 1-6.